Jun 5 • Christopher's Tea Talks
Christopher’s Weekly Kratom Tea Talks-June 4 2026-Community Support Group-Episode 43
Quick recap
Christopher, Venus, and Paul discussed recent legislative developments around kratom regulation, particularly focusing on FDA actions and state-level bans. Christopher shared his experience attending multiple advocacy meetings in Washington D.C., including congressional hearings where he testified about the differences between natural kratom and synthetic 7-OH products. The group debated the safety and regulation of 7-OH metabolites, with Christopher expressing concerns about unregulated synthetic products being marketed as kratom alternatives.
They discussed the challenges of educating policymakers and the public about kratom's benefits versus risks, with Venus sharing her positive meeting with Good Neighbors about potential assistance for home repairs. The conversation also covered industry quality standards, with Christopher explaining his company's strict testing protocols and GMP compliance, while expressing frustration about competitors selling untested products with misleading claims.
Summary
Meeting Registration and Animal Medication
Christopher and Venus discussed the registration status for an upcoming meeting, with 65 people registered. They had a casual conversation about a koala branding element from 2016 advocacy work, noting that koalas eat eucalyptus, not kratom. The discussion then shifted to animal self-medication behavior, with Christopher explaining the concept of zoo pharmacognosy and comparing it to human use of plants for medicinal purposes.
Kratom Legislation and Community Updates
Venus reported a successful meeting with Good Neighbors regarding potential assistance for basement and roof repairs, including information about a local roof contest. Christopher and Venus discussed ongoing concerns about kratom legislation in Philadelphia, with Christopher noting uncertainty about the final language of the bill and its potential impact on natural kratom. They also discussed the challenges of constant education needed for new community members about kratom, with Christopher sharing his experience at a local substance abuse prevention meeting where National Guard representatives demonstrated good knowledge of kratom issues.
Kratom Education and Safety Discussion
Christopher and Venus discussed their approach to educating people about kratom, emphasizing the importance of informed decision-making rather than promoting the substance directly. They highlighted that natural kratom is not the main issue, while synthetic alternatives like Thioneptine and Phenobut present greater concerns. The conversation also covered safety considerations, including proper dosage and potential interactions with medications, with both speakers agreeing that manufacturers must balance consumer safety with product accessibility.
Kratom Regulation Discussion
Christopher discussed recent legislative activities around Kratom regulations, including congressional hearings in Washington D.C. and Idaho, where he submitted testimony. He expressed concern about the lack of FDA approval for Kratom products and emphasized the need for federal KCPA legislation to provide a regulatory framework similar to hemp regulations. The group discussed how unregulated products containing unknown chemicals are being sold mainstream, with Christopher noting that manufacturers struggle to implement safeguards when consumers ignore safety advice.
708 Substance User Demographics Discussion
Christopher, Venus, and Paul discussed the demographics and characteristics of users of 708, a substance different from Kratom. They debated whether the target market is younger individuals in their twenties or older users seeking relief, with Christopher expressing curiosity about the actual target audience. The conversation also covered concerns about the unregulated nature of 708 products, highlighting inconsistencies in ingredient labeling and the presence of unexpected chemicals, as evidenced by testing results from websites like TestMyKratom.org and congressional hearings.
Kratom Potency Decline Discussion
Christopher and Paul discussed the decline in kratom potency over recent years, attributing it to overharvesting and younger leaves being used. They compared the quality of wild-harvested kratom from 2016-2017 to current market products, with Christopher noting that premium kratom still maintains consistent quality regardless of potency level. The conversation also touched on the challenges of selling natural kratom products versus enhanced alternatives, with Christopher emphasizing the importance of quality control and testing in the industry.
Kratom Discussion and Regulations
Paul and Christopher discussed their experiences with Kratom, with Paul expressing concerns about its strength and Christopher sharing his positive experiences while acknowledging the challenges in the industry. Christopher explained his health journey, including recent medical issues, and mentioned that doctors have suggested natural leaf tea may help slow down a genetic vascular condition. They discussed the FDA's handling of Kratom regulations, with both agreeing that while the FDA appears supportive overall, there may be resistance from older staff members, and they expressed optimism about the direction toward harm reduction and plant medicine.
Kratom Research and Regulatory Updates
Christopher and Paul discussed recent developments with NIH studies on kratom and mitragynine, with Christopher explaining that these studies prove the compound is safe enough for human trials and won't lead to a ban on kratom. They explored potential regulatory pathways and concerns about synthetic alternatives to kratom leaf, with Christopher noting that making strong extracts at home would not be financially feasible. The conversation concluded with Paul recommending a show featuring constitutional attorney Jonathan Emord about the pharmaceutical industry's efforts to downplay food as medicine.
Maha Media Hub Updates
Christopher shared information about the Maha Media Hub's weekly Wednesday 4 PM Zoom meetings, which feature discussions about the Maha movement and related topics, and provided Paul with the registration link and main website. Christopher expressed his confidence in natural kratom's safety based on his conversations with industry leaders like Kyle Diamantis and the recent appointment of a new acting FDA director. The discussion highlighted the ongoing challenges in advocating for kratom legislation, with Christopher noting that lawmakers often have predetermined positions and don't respond well to constituent input from out-of-state.
Kratom Legislation and Safety Concerns
Venus shared her positive experience meeting with a local Delaware senator who gave her contact information and agreed to continue researching kratom. Christopher discussed the importance of building personal relationships with legislators and mentioned a website called kratomindex.com that provides scientific information about kratom. The conversation focused on concerns about 708 kratom products, with Christopher expressing his opinion that the rapid increase in dosage from 15mg to 150mg tablets over a year has caused significant problems for users.
Kratom and Synthetic Alternatives Discussion
Christopher and Paul discussed the issues surrounding Kratom and synthetic alternatives like 70H, expressing concerns about false advertising and the impact on people struggling with addiction. They compared the effects of different substances, including CBD and THCA flower, and shared personal experiences. Christopher offered to send Paul some CBD products, jar openers, and a shirt, and they briefly discussed business matters.
Kratom Business Advocacy Strategy
Christopher discussed the challenges his small kratom business faces, including a significant drop in orders from 50-60 per day to 10-15, and the high costs associated with advocacy work in Washington DC. He proposed organizing a group trip to DC to educate policymakers about kratom and share personal stories with potential allies. Christopher explained his company's commitment to regulatory compliance, including developing comprehensive standard operating procedures and certifying suppliers through QR code verification systems.
Kratom Batch Shelf Life Discussion
Christopher discussed the shelf life of kratom batches, noting that a special reserve batch sold out in 4 months compared to the typical 6-8 months for most batches. The conversation then shifted to Christopher's desire to visit Indonesia to experience kratom cultivation firsthand, though he expressed concerns about flying due to his recent vascular surgery. The group discussed practical considerations including travel costs, health requirements, and climate adaptation challenges based on previous experiences of Indonesian workers visiting cold climates.
Kratom Advocacy Future Discussion
The group discussed the current state and future of kratom advocacy, highlighting past successes in preventing a ban and emphasizing the plant's potential benefits for pain management and addiction recovery. Christopher shared personal experiences with kratom use and its effectiveness in managing pain after surgery, while also noting the challenges in educating others about proper usage. The conversation concluded with reflections on the importance of continued advocacy and the group's commitment to supporting kratom's acceptance and integration into mainstream health solutions.
4
3 comments
Christopher’s Weekly Kratom Tea Talks-June 4 2026-Community Support Group-Episode 43
powered by
skool.com/christophers-kratom-education-8543
Christopher’s Kratom Education: clear, science-based kratom education, beginner walk-throughs, brewing tips, safety, policy, and community together.
Suggested communities
Powered by